Ramamoorthy, RameshR, MuraliRagavendraBalameena, S.2019-12-022019-12-022019Ramamoorthy RameshR MuraliRagavendraBalameena S.. Estimation of interleukin 1β levels in acute gout patients before and after colchicine. International Archives of Integrated Medicine. 2019 Nov; 6(11): 118-1232394-00262394-0034http://imsear.searo.who.int/handle/123456789/187350Gout is a debilitating condition that affects millions across the world. In gout, hyperuricemia results in the deposition of monosodium urate monohydrate crystals in joints and soft tissues. IL-1β, an interleukin has been shown to be the most prominent inflammatory marker in the pathogenesis of gout. This study was conducted to assess the IL-1β lowering effect of oral colchicine in gout patients. Forty gout patients were randomly divided into 2 groups and one group was treated with oral colchicine while the other group was treated with NSAIDs for a period of 2 months. Their serum IL1β levels were estimated before and after treatment. Baseline demographics were similar between the groups. It was found that IL-1β levels in the colchicine group were significantly lower than the IL-1β levels of the NSAID group. They also had better symptomatic relief. This study concluded that serum IL-1β was elevated in gout patients and colchicine was effective in lowering it.GoutIL1-βColchicineNSAIDSJournal ArticleIndiaAssistant Professor, Institute of Rheumatology, Madras Medical College, Chennai, Tamil Nadu, India, rameshr27@yahoo.comAssociate Professor, Department of Medical Gastroenterology, Madras Medical College, Chennai, Tamil Nadu, IndiaPost Graduate Student, Institute of Rheumatology, Madras Medical College, Chennai, Tamil Nadu, IndiaAssociate Professor, Department of Rheumatology, Kilpauk Medical College, Kilpauk, Chennai, Tamil Nadu, India